# q03 rev 0 - blind solver B (fresh blind-solver, packet solver-2), 2026-10-06

Raw return as received:

**answer:** 4.4%. The restatement took about $1.534 billion of revenue and $68.1 million of operating income out of U.S. Healthcare Solutions' quarter ended June 30, 2025. $68,143K ÷ $1,533,690K = 4.443%, which rounds to 4.4%.

**confidence:** high

**path:**
1. **The restatement (D06, Q4 FY2025 release, line 121, under "Reportable Segments (revised as of October 1, 2025)"):** "Beginning in the first quarter of fiscal 2026, the Company's reporting structure will be comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services)… Other… includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex."
2. **Figures as first reported (D04, Q3 FY2025 release, Summary Segment Information, "(in thousands)", lines 420–431):**
   - Revenue: "|U.S. Healthcare Solutions|$72,876,563|$67,191,598|8.5%|"
   - Operating income: "|U.S. Healthcare Solutions|$901,793|$698,305|29.1%|"
   - The narrative on line 79 matches: "$72.9 billion… up 29.1 percent".
3. **Same quarter after the restatement (D05, Q3 FY2026 release, Summary Segment Information, "(in thousands)", lines 453–465, 2025 column):**
   - Revenue: "|U.S. Healthcare Solutions|$74,860,763|$71,342,873|4.9%|"
   - Operating income: "|U.S. Healthcare Solutions|$966,178|$833,650|15.9%|"
   - Footnote on line 128 points to the "fiscal 2025 revised reportable segment information".
4. **Removed amounts:**
   - Revenue: 72,876,563 − 71,342,873 = 1,533,690 (thousands)
   - Operating income: 901,793 − 833,650 = 68,143 (thousands)
   - Margin: 68,143 ÷ 1,533,690 = 0.044431, or 4.443%, which rounds to **4.4%**.
5. **Checks:**
   - **Totals unchanged:** total Q3 FY2025 revenue is $80,663,532K in both D04 and D05, and total segment operating income is 1,058,331 in both.
   - **The pieces add up to Other:**
     - Revenue: 1,533,690 from U.S. Healthcare plus 537,042 from International (7,790,438 − 7,253,396) plus 36,732 from the larger intersegment elimination (3,469 became 40,201) equals Other's 2,107,464.
     - Operating income: 68,143 + 18,947 + 14 = 87,104, which equals Other.
   - **Margins match the table:** the original segment margin works out to 1.237% and the restated one to 1.169%. These match the printed 1.24% (D04) and 1.17% (D05).
   - **Same figures from other documents (original basis):** full-year less Q4 from D06 gives nine-month revenue of 290,982,023 − 75,788,501 = 215,193,522, which matches D04. Taking away D02's six-month 142,316,959 gives 72,876,563. Operating income works the same way: 3,574,699 − 872,412 − 1,800,494 = 901,793.
   - **Same figures from other documents (restated basis):** D05's nine-month 210,717,432 less D03's restated six-month 139,374,559 gives 71,342,873. Operating income: 2,465,544 − 1,631,894 = 833,650.

**minimal_documents:** D04 + D05.
- D02 + D06 can replace D04 (full year minus Q4 minus first half gives the originally reported Q3, as shown above).
- D05 can't be replaced. It is the only document with the restated Q3 FY2025 or nine-month FY2025 figures. D06 gives restated fiscal 2025 totals only, rounded to $285.0B and $3.3B.
- D06 is useful context for what the restatement was, but the calculation doesn't need it.

**readings:**
- **Rounded narrative figures:** using the press-release text ("$72.9 billion", "$0.9 billion") instead of the tables is too coarse to give one decimal place. For example, $68.1M ÷ $1.53B is about 4.45%, which is on the rounding edge. The exact thousands give 4.4%.
- **Other's whole margin:** Other's restated Q3 FY2025 margin is 87,104 ÷ 2,107,464 = 4.13%. That figure also includes businesses moved from International (Profarma, PharmaLex), so it isn't what the question asks.
- **Change in the segment's margin:** U.S. Healthcare Solutions' margin fell from 1.24% to 1.17%, a drop of 0.07 points. That's a different quantity from the margin on the removed amounts.

The question's wording supports only the 4.4% reading.

**gaps:**
- Exhibit 99.2 to the November 5, 2025 Form 8-K (the detailed revised segment data) isn't in the packet. It wasn't needed.
- All documents are text extractions with no PDF pages or layout files. The table rows were clean and matched their percentage-change columns and the narrative.
- **Read:**
  - D04: lines 73–84 and 405–514
  - D05: lines 1–140 and 440–564
  - D06: lines 1–170
- **Grep only:** segment rows in D02, D03 and D06.
- **Grep hits only:** D01.
- **Not read:**
  - The remaining reconciliation, balance-sheet and cash-flow sections.
  - The docs/ copies.
  - The packet's question.txt, deliberately.

**contaminated:** no
